Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcela F Pasetti

Showing results (111-120 of 172) with videos related to

Pageof 18
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 29, 2020
Respiratory Syncytial Virus (RSV) Neutralizing Antibodies at Birth Predict Protection from RSV Illness in Infants in the First 3 Months of LifeAndrea G Buchwald, Barney S Graham, Awa Traore, et al.
Vaccine|December 1, 2020
Adjustments for oral fluid quality and collection methods improve prediction of circulating tetanus antitoxin: Approaches for correcting antibody concentrations detected in a non-invasive specimenHenri Garrison-Desany, Benard Omondi Ochieng, Maurice R Odiere, et al.
Vaccine|January 26, 2021
Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testingDeAnna J Friedman-Klabanoff, Andrea A Berry, Mark A Travassos, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
Systemic and Mucosal Antibody Correlates of Protection Against Bordetella pertussis in a Controlled Human Infection ModelMehak Zahoor Khan, Yogita Kapoor, Evgenii Kliuchnikov, et al.
NPJ Vaccines|January 13, 2025
A broad spectrum Shigella vaccine based on VirG<sub>53</sub><sub>-</sub><sub>353</sub> multiepitope region produced in a cell-free systemGirmay Desalegn, Charlotte Abrahamson, K Ross Turbyfill, et al.
Clinical and Vaccine Immunology : CVI|June 9, 2017
Cytokines Are Markers of the Clostridium difficile-Induced Inflammatory Response and Predict Disease SeverityHua Yu, Kevin Chen, Ying Sun, et al.
Mbio|August 4, 2022
Mucosal Immune Profiles Associated with Diarrheal Disease Severity in <i>Shigella</i>- and Enteropathogenic Escherichia coli-Infected Children Enrolled in the Global Enteric Multicenter StudyAmanda D Buskirk, Esther Ndungo, Avital A Shimanovich, et al.
NPJ Vaccines|February 1, 2025
Safety and immunogenicity in humans of enterotoxigenic Escherichia coli double mutant heat-labile toxin administered intradermallyMarcela F Pasetti, Patricia L Milletich, Jessica A White, et al.
Msphere|August 3, 2018
A Novel <i>Shigella</i> Proteome Microarray Discriminates Targets of Human Antibody Reactivity following Oral Vaccination and Experimental ChallengeEsther Ndungo, Arlo Randall, Tracy H Hazen, et al.
Human Vaccines|October 17, 2007
Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free mediaKaren L Kotloff, Jakub K Simon, Marcela F Pasetti, et al.
Pageof 18

Showing results (111-120 of 172) with videos related to

Sort By:
Pageof 18
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 29, 2020
Respiratory Syncytial Virus (RSV) Neutralizing Antibodies at Birth Predict Protection from RSV Illness in Infants in the First 3 Months of LifeAndrea G Buchwald, Barney S Graham, Awa Traore, et al.
Vaccine|December 1, 2020
Adjustments for oral fluid quality and collection methods improve prediction of circulating tetanus antitoxin: Approaches for correcting antibody concentrations detected in a non-invasive specimenHenri Garrison-Desany, Benard Omondi Ochieng, Maurice R Odiere, et al.
Vaccine|January 26, 2021
Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testingDeAnna J Friedman-Klabanoff, Andrea A Berry, Mark A Travassos, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
Systemic and Mucosal Antibody Correlates of Protection Against Bordetella pertussis in a Controlled Human Infection ModelMehak Zahoor Khan, Yogita Kapoor, Evgenii Kliuchnikov, et al.
NPJ Vaccines|January 13, 2025
A broad spectrum Shigella vaccine based on VirG<sub>53</sub><sub>-</sub><sub>353</sub> multiepitope region produced in a cell-free systemGirmay Desalegn, Charlotte Abrahamson, K Ross Turbyfill, et al.
Clinical and Vaccine Immunology : CVI|June 9, 2017
Cytokines Are Markers of the Clostridium difficile-Induced Inflammatory Response and Predict Disease SeverityHua Yu, Kevin Chen, Ying Sun, et al.
Mbio|August 4, 2022
Mucosal Immune Profiles Associated with Diarrheal Disease Severity in <i>Shigella</i>- and Enteropathogenic Escherichia coli-Infected Children Enrolled in the Global Enteric Multicenter StudyAmanda D Buskirk, Esther Ndungo, Avital A Shimanovich, et al.
NPJ Vaccines|February 1, 2025
Safety and immunogenicity in humans of enterotoxigenic Escherichia coli double mutant heat-labile toxin administered intradermallyMarcela F Pasetti, Patricia L Milletich, Jessica A White, et al.
Msphere|August 3, 2018
A Novel <i>Shigella</i> Proteome Microarray Discriminates Targets of Human Antibody Reactivity following Oral Vaccination and Experimental ChallengeEsther Ndungo, Arlo Randall, Tracy H Hazen, et al.
Human Vaccines|October 17, 2007
Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free mediaKaren L Kotloff, Jakub K Simon, Marcela F Pasetti, et al.
Pageof 18